Sophia Genetics SA has partnered with Tyrolpath, the largest private pathology lab in western Austria, to bring advanced precision oncology solutions to the country. Through this collaboration, Tyrolpath will be the first lab in Austria to adopt MSK-IMPACT®-Flex powered by the SOPHiA DDM™ Platform. This integration leverages the proven MSK-IMPACT® assay from Memorial Sloan Kettering Cancer Center and SOPHiA GENETICS' cloud-based data analysis platform, enabling cost-efficient, flexible, and comprehensive genomic profiling (CGP) of solid tumors. The partnership aims to enhance cancer testing and advance precision oncology for Austrian patients, addressing the growing need for actionable genomic insights in cancer care.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief on December 04, 2025, and is solely responsible for the information contained therein.